Company Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 06:22:33 13/05/2026 am IST			5-day change	1st Jan Change
0.0730 ^AUD	-1.35%		-5.19%	-14.12%

06:27am	Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%	MT
16/04	Neurizon Therapeutics Raises Nearly AU$3 Million to Reduce Entitlement Offer Shortfall; Shares Fall 7%	MT

Business description: Neurizon Therapeutics Limited

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Number of employees: 4

Sales by Activity: Neurizon Therapeutics Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Corporate & Research	6L	8L	10L	8L	15.38L
Pharmaceutical - Epichem	31.36L	37.58L	31.13L	-	-
Inter-Segment Elimination	-71.31T	-82.03T	-2L	-	-

See all business segments

Geographical breakdown of sales: Neurizon Therapeutics Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Sweden	-	3L	-	-	-
USA	1L	2L	1L	-	-
Australia	7L	17.37L	26.87L	-	-
Switzerland	11.3L	10.43L	17.28T	-	-
Others	2L	96.09T	18.76T	-	-

See all geographic segments

Executive Committee: Neurizon Therapeutics Limited

Manager	Title	Age	Since
Daniel O'Connell DFI	Director of Finance/CFO	-	22/04/2025
Nicky Wallis CTO	Chief Tech/Sci/R&D Officer	-	31/05/2024
John Clark CEO	Chief Executive Officer	-	23/04/2024
Kathryn Williams LAW	General Counsel	-	17/04/2025
Stefan Ross SEC	Corporate Secretary	-	24/05/2024

See NEURIZON THERAPEUTICS LIMITED governance

Composition of the Board of Directors: Neurizon Therapeutics Limited

Director	Title	Age	Since
Marcus Hughes BRD	Director/Board Member	-	09/05/2024
Sergio Duchini CHM	Chairman	-	17/05/2024
Michael Thurn BRD	Director/Board Member	-	31/05/2024
Kathryn MacFarlane BRD	Director/Board Member	60	17/06/2024
Ross Murdoch BRD	Director/Board Member	-	08/05/2026

Composition of the Board of Directors

Shareholders: Neurizon Therapeutics Limited

Name	Equities	%	Valuation
Loon Tan Chek 5.255 %	3,90,00,000	5.255 %	2 M $
Marcus Hughes 1.981 %	1,47,00,943	1.981 %	866 621 $
Michael Thurn 0.3866 %	28,69,276	0.3866 %	169 144 $
Kathryn MacFarlane 0.0361 %	2,67,656	0.0361 %	15 778 $
Sergio Duchini 0.0361 %	2,67,656	0.0361 %	15 778 $

List of NEURIZON THERAPEUTICS LIMITED shareholders

Company details: Neurizon Therapeutics Limited

Neurizon Therapeutics Ltd.

385 Bourke Street

3000, Melbourne

+61 3 9692 7222

http://www.pharmaust.com

address Neurizon Therapeutics Limited(NUZ)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NEURIZON THERAPEUTICS LIMITED	-1.35%	-5.19%	-49.66%	-7.59%	4.12Cr
ELI LILLY AND COMPANY	+2.37%	+0.10%	+31.01%	+127.85%	86TCr
JOHNSON & JOHNSON	+1.28%	-0.57%	+45.49%	+39.48%	53TCr
ABBVIE INC.	+2.51%	+0.85%	+9.36%	+41.26%	36TCr
ROCHE HOLDING AG	-0.94%	-1.00%	+20.39%	+10.73%	33TCr
ASTRAZENECA PLC	+1.82%	+3.14%	+33.84%	+14.47%	29TCr
NOVARTIS AG	+1.93%	+2.08%	+26.42%	+25.26%	28TCr
MERCK & CO., INC.	+0.98%	-0.69%	+39.71%	-4.07%	27TCr
NOVO NORDISK A/S	-1.17%	+3.71%	-32.83%	-49.56%	21TCr
AMGEN INC.	+2.03%	+2.03%	+22.39%	+44.36%	18TCr
Average	+0.76%	+0.35%	+14.61%	+24.22%	33.09TCr
Weighted average by Cap.	+1.15%	+0.58%	+26.02%	+47.50%